Harrow Health, Inc.

NASDAQ:HROW

Drug Manufacturers - Specialty & Generic

Healthcare
$32.16 +0.29%

+$0.12 today

Market cap
$1.21B
Beta
0.28
P/E (TTM)
-104.7
EPS (TTM)
-$0.40
52W Low $28.54High $54.85

Volume 0.87M

Average 0.75M

HROW Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Harrow Health, Inc.NASDAQ: HROW

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $3.38M, compared with -$11.1M a year earlier. Trailing-twelve-month accounts payables was $9.87M.

Context

  • Accounts payables amounted to 1.7% of revenue in FY2025, down 17.1 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near $3.38M or moves back toward the trailing-twelve-month quarterly average of $2.47M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.38M-85.0% QoQ
Last fiscal yearDec 2025
-$4.61M-112.3% YoY
LTMMar 2026
$9.87M-72.1% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+130.4%——
1 year-112.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(4.61M) USD
Year-over-year change
-112.3%

Accounts Payables vs competitors

How HROW compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -72.1% is the 6th highest of 8, against a peer median of -44.5%.
  • Accounts payables amounts to 3.7% of revenue for HROW, versus a peer median of 4.5%.
HROW Competitors
Accounts Payables for HROW and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BLCOBausch + Lomb CorporationLTM Jun 2026$33.86M USD-44.5%-17.0%0.6%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$15.75M USD-130.0%+103.4%2.3%
HROWHarrow Health, Inc.LTM Mar 2026$9.87M USD-72.1%—3.7%
KODKodiak Sciences Inc.LTM Sep 2026$6.02M USD-14.9%+69.4%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$4.9M USD+28.5%+8.8%1472.1%
OCULOcular Therapeutix, Inc.LTM Mar 2026$2.83M USD+241.0%+12.6%5.4%
TTRXTurn Therapeutics Inc.LTM Mar 2026$1.67M USD———
OCSOculis Holding AGLTM Mar 2026CHF 1.63M CHF-62.8%—323.1%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$274K USD-97.7%+57.5%3.6%
Peer median (excluding HROW) —-44.5%+35.0%4.5%

Competitors are the stored peer set for HROW. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.01M)(14.09M)(24.41M)(17.48M)(5.14M)
Depreciation & Amortization2.4M3.67M12.34M14.54M19.68M
Deferred Income Tax00000
Stock-Based Compensation5.75M7.97M15.7M17.62M12.5M
Change in Working Capital(253K)(5.57M)(7.14M)(44.63M)185K
Accounts Receivables(1.83M)(1.86M)(30.34M)(80.23M)5.01M
Inventory(255K)(2.32M)(4.33M)165K(2.82M)
Accounts Payables1.73M933K31.8M37.5M(4.61M)
Other Working Capital103K(2.32M)(4.26M)(2.06M)2.6M
Other Non-Cash Items15.2M9.72M7.35M7.75M16.64M
Operating Cash Flow5.08M1.71M3.84M(22.2M)43.86M
Capital Expenditures(28.51M)(7.77M)(152.55M)(38.67M)(1.1M)
Acquisitions (Net)9.83M000(4.36M)
Purchases of Investments00000
Sales of Investments9.83M005.51M0
Other Investing Activities(36.55M)854K(151.09M)(37.08M)(215K)
Investing Cash Flow(18.69M)(1.74M)(152.55M)(33.16M)(5.46M)
Debt Repayment71.07M31.72M74.64M29.78M11.84M
Common Stock Issued022.66M64.52M0467K
Common Stock Repurchased00000
Dividends Paid(127K)0000
Other Financing Activities(19.12M)(234K)(12.63M)(1.25M)(25.04M)
Financing Cash Flow51.47M54.14M126.53M28.53M(12.72M)
Effect of Forex Changes00000
Net Change in Cash37.87M54.1M(22.19M)(26.84M)25.68M
Free Cash Flow(23.43M)(6.07M)(148.71M)(60.88M)42.76M

Harrow Health, Inc.

NASDAQ:HROW

Intrinsic Alpha fair value

Locked

Current Price

$32.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.